48,175 Shares in Moderna, Inc. $MRNA Acquired by Legal Advantage Investments Inc.

Legal Advantage Investments Inc. bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 48,175 shares of the company’s stock, valued at approximately $1,244,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Moderna in the second quarter valued at approximately $94,910,000. Vanguard Group Inc. boosted its holdings in shares of Moderna by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock valued at $1,150,743,000 after buying an additional 1,312,192 shares in the last quarter. Letko Brosseau & Associates Inc. boosted its holdings in shares of Moderna by 2.4% in the 2nd quarter. Letko Brosseau & Associates Inc. now owns 918,190 shares of the company’s stock valued at $25,333,000 after buying an additional 21,765 shares in the last quarter. SHANDA ASSET MANAGEMENT HOLDINGS Ltd purchased a new position in shares of Moderna in the 1st quarter valued at $28,350,000. Finally, Thrivent Financial for Lutherans raised its stake in Moderna by 600.7% during the 2nd quarter. Thrivent Financial for Lutherans now owns 92,999 shares of the company’s stock worth $2,566,000 after acquiring an additional 79,726 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the subject of several research analyst reports. Bank of America decreased their price objective on shares of Moderna from $24.00 to $21.00 and set an “underperform” rating for the company in a research note on Monday, November 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Moderna in a research report on Wednesday, October 8th. Leerink Partners raised their price target on Moderna from $15.00 to $18.00 and gave the stock an “underperform” rating in a research note on Friday, November 21st. Berenberg Bank set a $28.00 price objective on Moderna in a research note on Monday, November 17th. Finally, Barclays decreased their price objective on Moderna from $31.00 to $25.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $29.21.

Moderna Stock Down 0.2%

Shares of MRNA stock opened at $31.15 on Tuesday. The stock’s 50-day moving average price is $27.07 and its 200 day moving average price is $27.41. The stock has a market capitalization of $12.17 billion, a PE ratio of -3.86 and a beta of 1.11. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $48.92.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($2.15) by $1.64. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The company’s revenue was down 45.4% on a year-over-year basis. During the same period last year, the business posted $0.03 EPS. Analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the transaction, the director directly owned 3,924 shares of the company’s stock, valued at approximately $115,679.52. The trade was a 85.87% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.90% of the stock is currently owned by company insiders.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.